

Press release archive

Nature Publishing Group and BioCentury announce the second annual SciBX Summit on Innovation in Drug Discovery & Development

PRESS RELEASE FROM NATURE PUBLISHING GROUP

24 Jul 2013

Contact: Rachel Scheer
Corporate Public Relations, Nature Publishing Group
T: +1 212 451 8569
r.scheer@us.nature.com

Today BioCentury Publications, Inc. and Nature Publishing Group (NPG), are pleased to announce the second annual SciBX Summit on Innovation in Drug Discovery & Development. The Summit will be held October 29-30 in Boston, MA, at the Colonnade Hotel Boston.

The Summit will bring together key stakeholders from academia, biotech, pharma and the investment community with the goal of creating roadmaps for solving key translational issues in important emerging areas of drug discovery and development. This year's summit will consist of four tracks:

- **Non-coding RNAs as tools and targets**

The discovery of thousands of noncoding RNAs has contributed to a robust commercial landscape, but fundamental translational issues remain.

- **New models in neurological diseases**

This session will review the necessary next steps to reinvigorate the clinical translation field focusing specifically on schizophrenia, autism and depression.

- **CAR-based cellular therapies**

Chimeric antigen receptor (CAR)-based cell therapies first appeared in 2011 when clinical results from three CML patients showed impressive efficacy. CAR-based approaches still face a host of obstacles on the way to full implementation.

- **Epigenetics' second wind**

There are novel methyltransferases (HMTs) and BET bromodomains targets emerging as well as initial reports on druggable histone demethylases that herald a second wave of development in the epigenetics space.

This year's line-up of panelists includes James Audia (Constellation), Bruce Booth (Atlas Venture), Art Krieg (RaNa) and Stuart Schreiber (Broad Institute).

"It's a testimony to the success of the inaugural event and the continued support from our industry partners that we have increased the scale of the event so quickly to cover four sessions at this year's SciBX Summit," said Peter Collins, Ph.D., Director of the Nature Publishing Group Business Intelligence Unit.

"The SciBX Summit will bring key life science stakeholders together in the fields of ncRNAs, CAR-based cellular therapies, epigenetics and neurological diseases," said BioCentury Chairman Karen Bernstein, Ph.D. "The goal of the Summit is to identify and document critical areas where more research is needed to fulfill the promise offered by these dynamic and emerging fields of drug development."

The Summit is the result of a months-long process during which the SciBX editorial team convenes working groups of four to six key opinion leaders for each track. Following the Summit, the SciBX team will create a document outlining the conclusions of the Summit participants, with an emphasis on solving key problems in each of the four fields.

New for this year's Summit is the establishment of an Advisory Council that creates a link between the SciBX editorial team and companies at the forefront of innovative drug discovery. The 2013 Advisory Council includes Amgen Inc., AstraZeneca plc, Biogen Idec Inc., Merck & Co. Inc., GlaxoSmithKline plc., Novartis AG, and Sanofi.

To see a complete schedule of events and to register and reserve your seat at the SciBX Summit, go to <http://www.nature.com/natureconferences/sidds13/index.html>

For information on sponsorship opportunities, go to

<http://www.nature.com/natureconferences/sidss13/sponsors.html>. Or
<http://www.biocentury.com/conferences/scibxsummit/sponsors/benefits>

-ENDS-

About SciBX: Science-Business eXchange

SciBX: Science-Business eXchange is a joint publishing venture between BioCentury and Nature Publishing Group that identifies commercially promising translational science and assesses the next steps required to develop the technology. Every week, BioCentury and NPG senior business and science editors analyze life science research published around the globe to provide the SciBX audience in R&D, business development, academia and the venture capital community with an early lead on fresh science with investment potential.

About Nature Publishing Group (NPG)

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.

Focusing on the needs of scientists, *Nature* (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of Nature research journals and *Nature Reviews* journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including Nature News and NatureJobs plus access to Nature Network and Nature Education's Scitable.com. Scientific American is at the heart of NPG's newly-formed consumer media division, meeting the needs of the general public. For more information, please go to www.nature.com.

About BioCentury

BioCentury Publications, Inc. provides essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. For more information, visit www.biocentury.com and www.biocenturytv.com.

[About us](#)

[Contact us](#)

[Accessibility statement](#)

[Help](#)

[Privacy policy](#)

[Use of cookies](#)

[Legal notice](#)

[Terms](#)

[Naturejobs](#)

[Nature Asia](#)

[Nature Education](#)

[RSS web feeds](#)

Search:

go

SPRINGER NATURE

© 2019 Nature is part of Springer Nature. All Rights Reserved.

partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef, COUNTER and COPE